Cargando…

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer

Prostate cancer consists of secretory cells and a population of immature cells. The function of immature cells and their mutual relation with secretory cells are still poorly understood. Immature cells either have a hierarchical relation to secretory cells (stem cell model) or represent an inducible...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Leenders, Geert J. L. H., Sookhlall, Rajesh, Teubel, Wilma J., de Ridder, Corrina M. A., Reneman, Suzanne, Sacchetti, Andrea, Vissers, Kees J., van Weerden, Wytske, Jenster, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215704/ https://www.ncbi.nlm.nih.gov/pubmed/22110593 http://dx.doi.org/10.1371/journal.pone.0026753

Ejemplares similares

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling
por: Van Hemelryk, Annelies, et al.
Publicado: (2022)

Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer
por: Moll, Jan Matthijs, et al.
Publicado: (2022)

A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
por: Moll, Jan M., et al.
Publicado: (2019)

Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids
por: Van Hemelryk, Annelies, et al.
Publicado: (2023)

Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
por: Marques, Rute B., et al.
Publicado: (2010)

Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model()
por: Mout, Lisanne, et al.
Publicado: (2017)

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
por: Marques, Rute B., et al.
Publicado: (2011)

Overexpression of Full-Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation
por: Gasi, Delila, et al.
Publicado: (2011)

Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response
por: Zhang, Wenhao, et al.
Publicado: (2018)

Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer
por: Hoogland, A. Marije, et al.
Publicado: (2016)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

MET expression during prostate cancer progression
por: Verhoef, Esther I., et al.
Publicado: (2016)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
por: Mout, Lisanne, et al.
Publicado: (2021)

A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues
por: Schroeder, Rogier P. J., et al.
Publicado: (2010)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma
por: Stelloo, Suzan, et al.
Publicado: (2016)

Patient-Derived Xenograft Models in Cancer Research
por: van Weerden, Wytske M.
Publicado: (2021)

Androgen receptor profiling predicts prostate cancer outcome
por: Stelloo, Suzan, et al.
Publicado: (2015)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer
por: Böttcher, René, et al.
Publicado: (2015)

Differential tissue expression of extracellular vesicle‐derived proteins in prostate cancer
por: Duijvesz, Diederick, et al.
Publicado: (2019)

Role of the DNA damage response in prostate cancer formation, progression and treatment
por: Zhang, Wenhao, et al.
Publicado: (2019)

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatment
por: Zhang, Wenhao, et al.
Publicado: (2019)

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases
por: Böttcher, René, et al.
Publicado: (2016)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing
por: Van Hemelryk, Annelies, et al.
Publicado: (2021)

Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice
por: Korsten, Hanneke, et al.
Publicado: (2016)

On cribriform prostate cancer
por: Kweldam, Charlotte F., et al.
Publicado: (2018)

Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models
por: van de Merbel, Arjanneke F., et al.
Publicado: (2021)

Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations
por: Böttcher, René, et al.
Publicado: (2018)

Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair
por: Zhang, Wenhao, et al.
Publicado: (2019)

Comparison of RNA extraction kits and histological stains for laser capture microdissected prostate tissue
por: Kolijn, Kimberley, et al.
Publicado: (2016)

Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
por: Hassani, Mahmoud, et al.
Publicado: (2020)

Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer
por: Rodríguez-Blanco, Giovanny, et al.
Publicado: (2018)

Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer
por: Kolijn, Kimberley, et al.
Publicado: (2015)

Awe and anxiety for cancer cells: connecting scientists and patients in a holistic approach of metastasis research
por: Bronkhorst, Hildert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vme81qd94iq58afpbn7cqg4i9h